Karakasis, P.; Sagris, M.; Patoulias, D.; Koufakis, T.; Theofilis, P.; Klisic, A.; Fragakis, N.; El Tanani, M.; Rizzo, M.
Mitigating Increased Cardiovascular Risk in Patients with Obstructive Sleep Apnea Using GLP-1 Receptor Agonists and SGLT2 Inhibitors: Hype or Hope? Biomedicines 2024, 12, 2503.
https://doi.org/10.3390/biomedicines12112503
AMA Style
Karakasis P, Sagris M, Patoulias D, Koufakis T, Theofilis P, Klisic A, Fragakis N, El Tanani M, Rizzo M.
Mitigating Increased Cardiovascular Risk in Patients with Obstructive Sleep Apnea Using GLP-1 Receptor Agonists and SGLT2 Inhibitors: Hype or Hope? Biomedicines. 2024; 12(11):2503.
https://doi.org/10.3390/biomedicines12112503
Chicago/Turabian Style
Karakasis, Paschalis, Marios Sagris, Dimitrios Patoulias, Theocharis Koufakis, Panagiotis Theofilis, Aleksandra Klisic, Nikolaos Fragakis, Mohamed El Tanani, and Manfredi Rizzo.
2024. "Mitigating Increased Cardiovascular Risk in Patients with Obstructive Sleep Apnea Using GLP-1 Receptor Agonists and SGLT2 Inhibitors: Hype or Hope?" Biomedicines 12, no. 11: 2503.
https://doi.org/10.3390/biomedicines12112503
APA Style
Karakasis, P., Sagris, M., Patoulias, D., Koufakis, T., Theofilis, P., Klisic, A., Fragakis, N., El Tanani, M., & Rizzo, M.
(2024). Mitigating Increased Cardiovascular Risk in Patients with Obstructive Sleep Apnea Using GLP-1 Receptor Agonists and SGLT2 Inhibitors: Hype or Hope? Biomedicines, 12(11), 2503.
https://doi.org/10.3390/biomedicines12112503
